Efter de første 4 ugers opretholdt romiplostim trombocyttal ≥ 50 x 109/ l hos mellem 50% og 70% af patienterne i den 6 måneder lange behandlingsperiode i de placebokontrollerede undersøgelser.
Following the first 4-weeks of study romiplostim maintained platelet counts ≥ 50 x 109/ l in between 50% to 70% of patients during the 6 month treatment period in the placebo-controlled studies.